Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06921213

Comprehensive Ambulatory Antibiotics for the Treatment of Congenital Syphilis

Status
Not Yet Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
90 (estimated)
Sponsor
London School of Hygiene and Tropical Medicine · Academic / Other
Sex
All
Age
0 Days – 7 Days
Healthy volunteers
Not accepted

Summary

CARES-1 is a randomised, open-label, phase II pharmacokinetic (PK) and safety study of ambulatory antibiotics for the treatment of neonates with "all-risk" asymptomatic congenital syphilis.

Conditions

Interventions

TypeNameDescription
DRUGLinezolid (LZD)Ten day course. Oral Linezolid dosed at 10mg/kg twice a day.
DRUGAmoxicillinTen day course. Oral Linezolid dosed at 50mg/kg twice a day.
DRUGBenzathine Penicillin GSingle IM dose 50,000iu/kg

Timeline

Start date
2025-10-01
Primary completion
2026-12-31
Completion
2027-06-30
First posted
2025-04-10
Last updated
2025-05-04

Locations

3 sites across 3 countries: Indonesia, Malawi, South Africa

Source: ClinicalTrials.gov record NCT06921213. Inclusion in this directory is not an endorsement.

Comprehensive Ambulatory Antibiotics for the Treatment of Congenital Syphilis (NCT06921213) · Clinical Trials Directory